Form 4: Arcellx Chief Medical Officer Christopher Heery Reports Stock Transactions

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and derivative securities, including stock options, on July 1, 2024, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 1, 2024, Christopher Heery, the Chief Medical Officer of Arcellx, Inc., engaged in transactions involving the company's common stock and stock options.
• Heery acquired 7,036 shares of common stock through the exercise of stock options at a price of $6.28 and 12,964 shares at $15.
• He also sold 17,217 shares at a weighted average price of $55.2577 and 2,783 shares at a weighted average price of $56.195.
• These transactions were executed under a Rule 10b5-1 trading plan established on December 22, 2023.
• Following these transactions, Heery directly owns 12,061 shares of common stock.
• Heery also holds options to buy 80,173 shares at $6.28 and 190,205 shares at $15.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's prospects.

Key Dates